{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:10:01Z","timestamp":1748909401219,"version":"3.41.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A dolutegravir plus darunavir\/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this regimen as assessed by treatment discontinuation (TD) for any reason.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, observational, multicentre study. PWH started on dolutegravir plus darunavir\/cobicistat from 1 December 2015 to 31 December 2022 were included. The primary endpoint was the rate of TD for any reason. Survival analysis with the Kaplan\u2013Meier estimator was used to assess the probability of TD over time. Multiple Cox regression was used to estimate the probability of TD at 1\u2005year following regimen initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three hundred and twenty-seven subjects were included. At baseline, 63.6% of individuals had HIV RNA of &amp;lt;50\u2005copies\/mL. Primary resistance-associated mutations for NRTIs, NNRTIs, PIs and integrase inhibitors were documented in 88.0%, 70.0%, 24.5% and 6.6%, respectively. Median follow-up was 4\u2005years (IQR 3.3\u20136.9). Probability of TD was 8.3%, 13.0%, 18.0%, 22.0%, 25.0%, 30.0% and 35.0% after 1, 2, 3, 4, 5, 6 and 7\u2005years of treatment, respectively. TD occurred in 83 subjects, largely due to death (n\u200a=\u200a20), simplification (n\u200a=\u200a13), toxicity (n\u200a=\u200a11), intolerance (n\u200a=\u200a9), drug interactions (n\u200a=\u200a10) and virological failure (n\u200a=\u200a7). At Cox regression analysis, factors associated with a higher probability of TD over time were baseline HIV RNA of &amp;gt;50\u2005copies\/mL (HR\u200a=\u200a2.14, 95% CI 1.20\u20133.81; P\u200a=\u200a0.01) and the presence of PI or integrase strand transfer inhibitor resistance mutations (HR\u200a=\u200a5.48, 95% CI 2.42\u201312.4; P\u200a&amp;lt;\u200a0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dolutegravir plus darunavir\/cobicistat is a durable combination in heavily treatment-experienced PWH. Those who were viraemic at the time of switch were more likely to discontinue, although most reasons for TD were other than virological failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf119","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:33:31Z","timestamp":1744216411000},"page":"1665-1672","source":"Crossref","is-referenced-by-count":0,"title":["Long-term durability of dolutegravir plus darunavir\/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study)"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-6668","authenticated-orcid":false,"given":"Diego","family":"Ripamonti","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Comi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Francavilla","sequence":"additional","affiliation":[{"name":"FROM\u2014Fondazione per la Ricerca Ospedale di Bergamo\u2014ETS , Bergamo ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Valenti","sequence":"additional","affiliation":[{"name":"FROM\u2014Fondazione per la Ricerca Ospedale di Bergamo\u2014ETS , Bergamo ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Cossu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco , Milano ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Moschese","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco , Milano ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lapadula","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca , Monza ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Mezzadri","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca , Monza ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca , Monza ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Molecular Medicine, Padua University Hospital , Padova ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Molecular Medicine, Padua University Hospital , Padova ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia , Pavia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layla","family":"Pagnucco","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia , Pavia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, Infectious and Tropical Diseases Unit, University Hospital of Siena , Siena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Bini","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases, University of Milan, ASST Santi Paolo e Carlo , Milano ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Virology Unit, University of Siena , Siena ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco , Milano ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025060219523011500_dkaf119-B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"author":"EACS","key":"2025060219523011500_dkaf119-B2"},{"key":"2025060219523011500_dkaf119-B3","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dky571","article-title":"Pharmacokinetics of dolutegravir with and without darunavir\/cobicistat in healthy volunteers","volume":"74","author":"Elliot","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025060219523011500_dkaf119-B4","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/jac\/dkx105","article-title":"Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study","volume":"72","author":"Spinner","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025060219523011500_dkaf119-B5","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1093\/jac\/dkaa234","article-title":"Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study","volume":"75","author":"Weidlich","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025060219523011500_dkaf119-B6","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/jac\/dkx055","article-title":"Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference","volume":"72","author":"Gervasoni","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025060219523011500_dkaf119-B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/FTD.0000000000001259","article-title":"The case of dolutegravir plus darunavir antiretroviral regimens: is it always useful to double the drug doses?","volume":"47","author":"Cattaneo","year":"2025;","journal-title":"Ther Drug Monit"},{"key":"2025060219523011500_dkaf119-B8","doi-asserted-by":"publisher","first-page":"ofaa356","DOI":"10.1093\/ofid\/ofaa356","article-title":"Efficacy and safety of switching to dolutegravir with boosted darunavir in virologically suppressed adults with HIV-1: a randomized, open-label, multicenter, phase 3, noninferiority trial: the DUALIS study","volume":"7","author":"Spinner","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025060219523011500_dkaf119-B9","doi-asserted-by":"publisher","first-page":"ofad542","DOI":"10.1093\/ofid\/ofad542","article-title":"A randomized trial of dolutegravir plus darunavir\/cobicistat as a switch strategy in HIV-1-infected patients with resistance to at least 2 antiretroviral classes","volume":"10","author":"Santos","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025060219523011500_dkaf119-B10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/15284336.2018.1550290","article-title":"Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects","volume":"19","author":"Capetti","year":"2018","journal-title":"HIV Clin Trials"},{"key":"2025060219523011500_dkaf119-B11","doi-asserted-by":"publisher","first-page":"e0210476","DOI":"10.1371\/journal.pone.0210476","article-title":"Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients","volume":"14","author":"Jab\u0142onowska","year":"2019","journal-title":"PLoS One"},{"key":"2025060219523011500_dkaf119-B12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3851\/IMP3330","article-title":"Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals","volume":"24","author":"Hawkins","year":"2019","journal-title":"Antivir Ther"},{"key":"2025060219523011500_dkaf119-B13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/phar.2227","article-title":"Effectiveness of once\/day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus","volume":"39","author":"Navarro","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2025060219523011500_dkaf119-B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3851\/IMP3319","article-title":"Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients","volume":"24","author":"Vizcarra","year":"2019","journal-title":"Antivir Ther"},{"key":"2025060219523011500_dkaf119-B15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/hiv.13062","article-title":"Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice","volume":"22","author":"Armenia","year":"2021","journal-title":"HIV Med"},{"key":"2025060219523011500_dkaf119-B16","doi-asserted-by":"publisher","first-page":"106403","DOI":"10.1016\/j.ijantimicag.2021.106403","article-title":"Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV","volume":"58","author":"Lee","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2025060219523011500_dkaf119-B17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3947\/ic.2024.0006","article-title":"Effectiveness and tolerability of dual therapy with dolutegravir plus darunavir\/cobicistat in treatment-experienced patients with HIV: a 144-week follow-up","volume":"56","author":"Kim","year":"2024","journal-title":"Infect Chemother"},{"key":"2025060219523011500_dkaf119-B18","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","article-title":"Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b\/4 trial","volume":"11","author":"D2EFT Study Group","year":"2024","journal-title":"Lancet HIV"},{"key":"2025060219523011500_dkaf119-B19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/jac\/dkv427","article-title":"Antiretroviral resistance at virological failure in the NEAT 001\/ANRS 143 trial: raltegravir plus darunavir\/ritonavir or tenofovir\/emtricitabine plus darunavir\/ritonavir as first-line ART","volume":"71","author":"Lambert-Niclot","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025060219523011500_dkaf119-B20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/v13020205","article-title":"Integrase strand transfer inhibitors are effective anti-HIV drugs","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"key":"2025060219523011500_dkaf119-B21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1097\/QAD.0000000000001058","article-title":"Once-daily maraviroc versus tenofovir\/emtricitabine each combined with darunavir\/ritonavir for initial HIV-1 treatment","volume":"30","author":"Stellbrink","year":"2016","journal-title":"AIDS"},{"key":"2025060219523011500_dkaf119-B22","doi-asserted-by":"publisher","first-page":"ofz531","DOI":"10.1093\/ofid\/ofz531","article-title":"Polypharmacy, drug\u2013drug interactions, and inappropriate drugs: new challenges in the aging population with HIV","volume":"6","author":"Courlet","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025060219523011500_dkaf119-B23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2025060219523011500_dkaf119-B24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025060219523011500_dkaf119-B25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/QAD.0000000000002941","article-title":"Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status","volume":"35","author":"Mican","year":"2021","journal-title":"AIDS"},{"author":"Welford","key":"2025060219523011500_dkaf119-B26"},{"key":"2025060219523011500_dkaf119-B27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/QAI.0000000000003239","article-title":"Brief report: Hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion","volume":"94","author":"Vasishta","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060219523011500_dkaf119-B28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3201\/eid3008.240019","article-title":"Hepatitis B virus reactivation after switch to cabotegravir\/rilpivirine in patient with low hepatitis B surface antibody","volume":"30","author":"Adachi","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2025060219523011500_dkaf119-B29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2014.66","article-title":"Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat","volume":"86","author":"Lepist","year":"2014","journal-title":"Kidney Int"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1665\/62898445\/dkaf119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1665\/62898445\/dkaf119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:52:40Z","timestamp":1748908360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/6\/1665\/8109335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf119","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,9]]}}}